Key result
Cardiomyocyte HSPB1 silencing lowers post-MI LVEF by ~16 percentage points and exacerbates myocardial fibrosis.
Why the study?
Myocardial fibrosis after myocardial infarction is promoted by TGF-β1-driven EndoMT, but whether cardiomyocyte heat shock protein B1 regulates this pathway was unknown.
Does cardiomyocyte-targeted HSPB1 modulation prevent post-infarction endothelial-to-mesenchymal transition and fibrotic remodeling in a mouse myocardial infarction model?
Does cardiomyocyte-targeted HSPB1 modulation prevent post-infarction endothelial-to-mesenchymal transition and fibrotic remodeling in a mouse myocardial infarction model?
Absolute Event Rate: 44.15% vs 60.55%
Cardiomyocyte-derived HSPB1 protects against post-infarction myocardial fibrosis by modulating redox conditions to restrain TGF-β1 maturation and inhibit endothelial-to-mesenchymal transition.
HSPB1 silencing worsens post-MI remodeling in mice; leaves open whether targeted overexpression could preserve function before clinical testing.
Myocardial fibrosis after myocardial infarction is promoted by endothelial-to-mesenchymal transition (EndoMT) driven by TGF-β1. We investigated whether cardiomyocyte heat shock protein B1 (HSPB1) shapes this pathway. In mouse infarction models, cardiomyocyte-targeted HSPB1 overexpression reduced collagen deposition and preserved ventricular function, whereas HSPB1 knockdown exacerbated fibrosis and EndoMT activation. In endothelial assays, HSPB1 attenuated TGF-β1-induced Smad2/3 phosphorylation and mesenchymal marker expression. Mechanistically, HSPB1 modulated redox conditions to restrain disulfide-bond formation during pro-TGF-β1 maturation, reducing the secretion of mature TGF-β1. These results link cardiomyocyte redox homeostasis with paracrine control of endothelial plasticity and support HSPB1 as a therapeutic entry point to limit post-infarction fibrotic remodeling.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied Myocardial infarction and myocardial fibrosis. Targeted HSPB1 silencing (AAV9-HSPB1-RNAi) vs. Control virus (CON534) was evaluated on Left ventricular ejection fraction (LVEF%). Cardiomyocyte-targeted HSPB1 silencing significantly reduced left ventricular ejection fraction (44.15% vs 60.55%) and exacerbated myocardial fibrosis and EndoMT activation in mouse infarction models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: